This report on the global osteoarthritis treatment market studies various types of therapeutics used for the treatment of osteoarthritis, along with pipeline analysis of upcoming potential drugs. Globally, osteoarthritis is the eighth leading cause of disability, with the joint most frequently associated with disability being the knee. Unfortunately, the current treatment for osteoarthritis is incapable due to lack of efficacy and serious side effects associated with long-term use. Thus, the the osteoporosis treatment market drug pipeline comprises potential drugs withss high efficacy, fewer side effects, and innovative properties.
For this study, the various therapeutic type considered are analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and hyaluronic acid. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn and the respective CAGRs for 2016 to 2022, considering 2015 as the base year.
The pipeline analysis for the osteoarthritis treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Sprifermin (Merck Serono), Invossa (TissueGene), Ampion (Ampio Pharmaceuticals. Inc.), Apitox (Apimeds, Inc.), Fasinumab (Regeneron Pharmaceuticals), LBSA0103 (LG Life Sciences), and AXS-02 (Axsome Therapeutics, Inc.). In addition, the report also covers qualitative information associated with the drugs under phases II and I of the clinical trials.
The geographic segmentation of the global osteoarthritis treatment market is performed for the regions of North America, Europe, Asia Pacific, and the Rest of the World markets. The regions are also further sub-segmented based on major countries. Market size estimates and forecasts for these segments for 2013 to 2022 are provided in terms of USD Mn and the respective CAGRs for 2016 to 2022, considering 2015 as the base year.
The key players covered in the osteoarthritis treatment market are Abbott Laboratories, Johnson & Johnson Limited, Novartis AG, Pfizer, Inc., Abiogenic Pharma Spa, Ampio Pharmaceuticals, BioDelivery Sciences International, Inc., Eli Lilly and Company, Merck & Co., Sanofi SA, and Smith & Nephew, Inc.
Type of Therapeutics Segmentation Analysis
According to Arthritis Foundation, osteoarthritis is a chronic (long-term) disease with no cure, but treatments are available to manage symptoms. The National Institute of Aging suggests that osteoarthritis treatment includes several ways to manage pain and improve function with the help of exercise, rest and joint care, pain relief, weight control, medicines, surgery, and non-traditional treatment approaches.
Based on the type of therapeutics, the osteoarthritis treatment market is segmented into:
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Hyaluronic Acid
A combined data extracted from published reports of the Centers for Disease Control and Prevention (CDC) and the National Health Interview Survey (NHIS) suggests that in the U.S., overall, 22.7% (52.5 million) of adults reported doctor-diagnosed arthritis, with significantly higher age-adjusted prevalence in 2010 – 2012 it was observed that women (23.9%) patient was more than men (18.6%) patients and arthritis prevalence increases with age.
By 2040, an estimated 78 million (26% of the projected total adult population) adults aged 18 years and older will have doctor-diagnosed arthritis, compared with the 52.5 million adults in 2010 – 2012. In the base year 2015, the NSAIDs and corticosteroids collectively attribute the largest share in the market in terms of revenue (USD). The pain and loss of function can be unbearable; in developed countries, the resultant socioeconomic burden is large, costing between 1.0% and 2.5% of gross domestic product.
The treatment observed in osteoarthritis has been patient-specific; however, pain management in osteoarthritis is considered the most important factor, which is currently carried out with the help of NSAIDs and corticosteroids as the first choice. However, a recent study published in the Lancet by Dr. Sven Trelle of the University of Bern in Switzerland covered that acetaminophen (paracetamol) was only marginally better than a placebo for treating symptoms of degenerative joint disease.
Furthermore, diclofenac was observed as the most effective short-term pain relief from osteoarthritis. However, due to its side effects, Dr. Sven Trelle and colleagues recommended taking the medication long-term. Hence, shortly, drugs in the pipeline with fewer side effects and high efficiency will be responsible for declining market shares of NSAIDs and corticosteroids in the osteoarthritis treatment market.
For this study, the global osteoarthritis treatment market is categorized into:
- North America
- Asia Pacific
- Rest of the World
North America was observed as the largest market for osteoarthritis treatment in the base year 2015. According to the Centers for Disease Control and Prevention (CDC), in 2015 the U.S. comprises, 62% of adults with arthritis are